Evaluation of Ingenol Mebutate for Actinic Cheilitis Treatment
Status:
Withdrawn
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Actinic cheilitis is a major potentially carcinogenic disorder of the lower lip and several
reports of clinical cases with excellent results for the treatment of this lesion that can
differentiate to squamous cell carcinoma of the lip. However, clinical trials are lacking to
define the optimal dosage of the drug for a therapeutic modality and to define its true
efficacy in controlled studies of this pre-malignant labial lesion.